Surat, Feb 14: Anupam Rasayan India Limited, one of India’s leading custom synthesis and specialty chemical companies, today announced its financial results for the quarter ended December 31, 2025 (Q3 FY26), reporting strong year-on-year growth in revenue and profitability.
Q3 FY26 Consolidated Financial Highlights
- Total Revenue: ₹5,145 million in Q3 FY26, compared to ₹3,866 million in Q3 FY25, marking a 33% YoY growth
- EBITDA (including other income): ₹1,296 million in Q3 FY26 versus ₹1,208 million in Q3 FY25, reflecting 7% YoY growth
- EBITDA Margin: 25.20%
- Profit After Tax (PAT): ₹606 million in Q3 FY26, compared to ₹542 million in Q3 FY25, registering 12% YoY growth
For the nine months ended FY26, the Company reported consolidated revenue of ₹17,297 million and EBITDA of ₹4,024 million, demonstrating sustained operational momentum and improved scale efficiencies.
Management Commentary
Commenting on the performance, Mr. Anand Desai, Managing Director, Anupam Rasayan India Limited, said:
“I am pleased to share that for the nine months of FY26, we delivered consolidated revenue of ₹17,297 million with EBITDA of ₹4,024 million, reflecting strong year-on-year growth. For Q3 FY26, revenue stood at ₹5,145 million with EBITDA of ₹1,296 million, demonstrating continued growth momentum.
A significant strategic development during the period has been the signing of a definitive agreement to acquire Jayhawk Fine Chemicals Corporation in the United States. This acquisition strengthens our global footprint, enhances our capabilities in advanced custom synthesis, and deepens our access to regulated markets and innovator customers in North America. It represents an important step in our journey toward becoming a global specialty chemical platform.”
Strategic Developments
During the quarter, the Company signed a definitive agreement to acquire Jayhawk Fine Chemicals Corporation, a U.S.-based specialty chemical manufacturer. The acquisition is expected to:
- Strengthen ARIL’s presence in North America
- Enhance advanced custom synthesis capabilities
- Expand access to regulated markets
- Broaden relationships with innovator pharmaceutical and specialty chemical customers
This move aligns with the Company’s long-term strategy of building a global, innovation-driven specialty chemical platform.
